再発性多発性硬化症および一次性進行性多発性硬化症患者におけるオクレリズマブの有効性、安全性、薬物動態、薬力学を評価する研究
中国の再発型多発性硬化症および原発性進行型多発性硬化症患者におけるオクレリズマブの有効性、安全性、薬物動態、薬力学を評価する多施設共同、非盲検、単一投与群研究
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Beijing、中国、100034
- Peking University First Hospital
-
Beijing、中国、100032
- Peking Union Medical College Hospital
-
Beijing、中国、100730
- Beijing Hospital of Ministry of Health
-
Changsha、中国、410008
- Xiangya Hospital Central South University
-
Chengdu、中国、610041
- West China Hospital of Sichuan University
-
Chongqing、中国、400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou、中国、510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou、中国、510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Hangzhou、中国、310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
Hohhot、中国、010011
- Inner Mongolia Autonomous Region People's Hospital
-
Lanzhou、中国、730030
- Lanzhou University Second Hospital
-
Shenyang、中国、DUMMY_VALUE
- The First Hospital of China Medical University
-
Shijiazhuang、中国、050000
- The Second Hospital of Hebei Medical University
-
Taiyuan、中国、030000
- 1st Affiliated Hospital of Shanxi Medical University
-
Wuhan、中国、430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Ürümqi、中国、830000
- Xinjiang People Hospital
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330209
- The First Affiliated Hospital of Nanchang University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
- EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
- Documented MRI of brain with abnormalities consistent with MS before screening
Exclusion Criteria:
- Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
- History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
- Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
- History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- Inability to complete an MRI scan or contraindication to Gd administration
- Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Known history of human immunodeficiency virus (HIV) infection
- Lack of peripheral venous access
- Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
- Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:RMS Cohort
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
他の名前:
|
|
実験的:PPMS Cohort
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
RMSコホート:年率換算プロトコル定義再発率
時間枠:最大約1.6年
|
最大約1.6年
|
|
PPMSコホート:血液中のB細胞レベル
時間枠:最大48週間
|
最大48週間
|
|
PPMSコホート:週48時点で分化クラスター19(CD19+)B細胞レベルが<10細胞/マイクロリットル(μL)を達成した参加者の割合
時間枠:48週目に
|
48週目に
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
RMSコホート:48週間の期間中に疾患活動性の証拠がない(NEDA3)参加者の割合
時間枠:最大48週間
|
最大48週間
|
|
|
RMSコホート:48週時点の無再発参加者の割合
時間枠:最大48週間
|
最大48週間
|
|
|
RMSコホート:24週間の期間中にNEDA3を達成した参加者の割合
時間枠:最長24週間まで
|
最長24週間まで
|
|
|
RMSコホート:脳磁気共鳴画像法(MRI)で検出されたT1ガドリニウム(Gd)増強病変の総数
時間枠:48週間まで
|
48週間まで
|
|
|
RMSコホート:脳MRIで検出された新規または増大T2高信号病変の総数
時間枠:最大48週間
|
最大48週間
|
|
|
RMSおよびPPMSコホート:ベースラインから48週目までの血清神経フィラメント軽鎖(Nfl)濃度の変化
時間枠:ベースラインから48週まで
|
ベースラインから48週まで
|
|
|
RMSおよびPPMSコホート:オクレリズマブの血清濃度
時間枠:最長48週間
|
最長48週間
|
|
|
RMSコホート:血液中のB細胞レベル
時間枠:最大48週まで
|
最大48週まで
|
|
|
RMSコホート:48週目にCD19+ B細胞レベルが<10細胞/μLを達成した参加者の割合
時間枠:週48時点
|
週48時点
|
|
|
PPMSコホート:週24および週48の脳MRIで検出されたT1 Gd造影病変の総数
時間枠:第24週および第48週
|
第24週および第48週
|
|
|
PPMSコホート:週24および週48における脳MRIで検出された新規または拡大するT2高信号病変の総数
時間枠:週24および週48
|
週24および週48
|
|
|
RMSおよびPPMSコホート:有害事象(AE)が発生した参加者数
時間枠:約1.8年まで
|
約1.8年まで
|
|
|
RMSおよびPPMSコホート:ベースラインからのT細胞レベルの変化
時間枠:最大約1.8年
|
最大約1.8年
|
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
時間枠:Baseline up to Week 48
|
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
時間枠:Baseline up to Week 48
|
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
時間枠:Baseline up to Week 48
|
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
時間枠:Baseline, Week 48
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. |
Baseline, Week 48
|
|
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:Up to approximately 1.8 years
|
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior. |
Up to approximately 1.8 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Trials、Hoffmann-La Roche
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- YN44938
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。